Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 43

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 43
---
 coverage and patent position. Competing products and product candidates could present superior treatment alternatives,
including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive
products and product candidates may make any product we develop obsolete or noncompetitive before we recover the expense of developing
and commercializing such product. Such competitors could also recruit our employees, which could negatively impact our level of expertise
and our ability to execute our business plan.

These competitors also compete
with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and patient registration
for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive or better reimbursed than any products that we may commercialize. Our
competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours,
which could result in our competitors establishing a strong market position for either the product or a specific indication before we
are able to enter the market.

We are highly dependent on our key personnel, including individuals with expertise in cell therapy development and manufacturing, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in
the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. We are highly dependent on the expertise of our management, scientific and medical personnel, including
our chief executive officer (“Chief Executive Officer”), Chris Ehrlich, our chief development officer (“Chief Development
Officer”), Kristen Pierce, our chief financial officer (“Chief Financial Officer”), Al Kucharchuk and the head of our
scientific advisory board (the “Scientific Advisory Board”), Lawrence Corey. The loss of the services of any of our executive
officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result
in delays in product development and harm our business.

<div align='center'>19</div>

We conduct substantially
all of our operations at our facilities in the South San Francisco area. The San Francisco Bay Area region